Editas Medicine (EDIT) Q3 2026 earnings summary

Executive summary

• Q3 2026 collaboration and other R&D revenue was $10.4M, up 37% YoY; net loss narrowed to $23.4M from $25.1M.

• EDIT-401 advanced toward first-in-human dosing in 2026; cash and marketable securities of $190.2M supported an expected runway into H2 2028.

Financial highlights

• Q3 revenue was $10.4M versus $7.5M, primarily reflecting a strategic partner milestone; operating loss was $24.3M versus $24.5M.

• Q3 R&D expense was $21.2M versus $19.8M, and G&A expense was $13.5M versus $12.3M YoY.

• 9M revenue was $25.1M versus $15.8M; net loss was $66.6M versus $154.4M, with 2025 including $66.9M of restructuring and impairment charges.

• 9M operating cash use was $73.8M versus $128.9M; financing provided $117.1M, primarily from the May offering.

Outlook and guidance

• EDIT-401 Strive patient dosing remained on track for 2026; initial safety and tolerability data were expected in Q1 2027, with Part 1 topline safety and efficacy results targeted for H2 2027.

• Cash, cash equivalents and marketable securities at September 30 were expected to fund operating expenses and capital expenditures into H2 2028; the forecast is subject to assumptions and could vary materially.

• R&D expenses were expected to increase to support EDIT-401 clinical development and other preclinical programs; profitability was not expected in FY 2026 or the foreseeable future.